Building the Ideal Bioprocessing Strategy
Searching for Innovative, Cost-Effective Product Options
Innovations in Viral Clearance
Mock Viruses, Plant Design, and Rational Testing
Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals
Goal Is the Development of Faster, More Affordable Therapies
Top 10 European Biopharma Clusters
As Brexit Casts Uncertain Shadow, Continent’s Industry Continues Growth Trajectory
For full access to this article login to GEN Select now.
Novel ADMET Technologies Gain Traction
- Too many new drug compounds fail in late-stage clinical trials due to inefficacy and safety concerns. With often-cited costs of $800 million to bring a new drug to market, a compelling need exists for improved early-stage screening. Insufficient knowledge of potential human toxicity can turn a promising lead candidate ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.